FLUOROPHARMA MEDICAL, INC. - FORM 10-K - EX-23.1 - CONSENT OF WOLF & COMPANY, P.C. - March 31, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - FLUOROPHARMA MEDICAL, INC.Financial_Report.xls
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934. - FLUOROPHARMA MEDICAL, INC.ex31-1.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 1350. - FLUOROPHARMA MEDICAL, INC.ex32-1.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 1350. - FLUOROPHARMA MEDICAL, INC.ex32-2.htm
EX-10.13 - SECOND AMENDMENT TO LEASE AGREEMENT BETWEEN HILSSIDE SQUARE, LLC AND FLUOROPHARMA MEDICAL, INC. DATED AS OF FEBRUARY 2015 - FLUOROPHARMA MEDICAL, INC.leaseam.htm
10-K - FORM 10-K - FLUOROPHARMA MEDICAL, INC.fpmi10k_dec312014.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934. - FLUOROPHARMA MEDICAL, INC.ex31-2.htm
Exhibit 23.1
 
Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in Registration Statement (No. 333-185648) on Form S-8 of FluoroPharma Medical, Inc. of our report dated March 31, 2015, relating to our audit of the consolidated financial statements, which appear in this Annual Report on Form 10-K of FluoroPharma Medical, Inc. for the years ended December 31, 2014 and 2013. Our report dated March 31, 2015, relating to the consolidated financial statements includes an emphasis paragraph relating to an uncertainty as to the Company's ability to continue as a going concern.

/s/ Wolf & Company, P.C.
Boston, Massachusetts
March 31, 2015


FLUOROPHARMA MEDICAL, INC. Reports